Shares of MyoKardia, Inc. (NASDAQ:MYOK) have received a consensus recommendation of “Buy” from the six analysts that are presently covering the company. One investment analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $25.00.
Several equities research analysts have recently weighed in on MYOK shares. Zacks Investment Research downgraded MyoKardia from a “buy” rating to a “hold” rating in a report on Tuesday, January 10th. Wedbush reiterated an “outperform” rating and issued a $24.00 price target on shares of MyoKardia in a report on Monday, November 7th. Finally, Cowen and Company reiterated a “buy” rating and issued a $28.00 price target on shares of MyoKardia in a report on Tuesday, November 8th.
A number of hedge funds have recently made changes to their positions in the stock. Bessemer Group Inc. acquired a new stake in MyoKardia during the fourth quarter worth $114,000. Aberdeen Asset Management PLC UK acquired a new stake in MyoKardia during the fourth quarter worth $144,000. Trexquant Investment LP acquired a new stake in MyoKardia during the fourth quarter worth $210,000. Bank of New York Mellon Corp boosted its stake in MyoKardia by 84.7% in the second quarter. Bank of New York Mellon Corp now owns 21,503 shares of the company’s stock worth $267,000 after buying an additional 9,861 shares during the last quarter. Finally, California State Teachers Retirement System boosted its stake in MyoKardia by 75.4% in the second quarter. California State Teachers Retirement System now owns 23,599 shares of the company’s stock worth $293,000 after buying an additional 10,148 shares during the last quarter. 45.34% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “MyoKardia, Inc. (MYOK) Receives $25.00 Consensus PT from Brokerages” was posted by sleekmoney and is owned by of sleekmoney. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be accessed at http://sleekmoney.com/myokardia-inc-myok-receives-25-00-consensus-pt-from-brokerages/1656428.html.
Shares of MyoKardia (NASDAQ:MYOK) opened at 12.25 on Tuesday. The company’s market capitalization is $384.99 million. MyoKardia has a 12 month low of $6.60 and a 12 month high of $22.83. The stock has a 50 day moving average price of $12.50 and a 200-day moving average price of $16.08.
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that results from biomechanical defects in cardiac muscle contraction. It is engaged in the business of developing and commercializing therapeutics.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/myokardia-inc-myok-receives-25-00-consensus-pt-from-brokerages/1656428.html
Receive News & Ratings for MyoKardia Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MyoKardia Inc. and related companies with MarketBeat.com's FREE daily email newsletter.